Market Cap 10.74M
Revenue (ttm) 0.00
Net Income (ttm) -12.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.54
Volume 13,180,300
Avg Vol 44,696,727
Day's Range N/A - N/A
Shares Out 107.48M
Stochastic %K 23%
Beta 0.86
Analysts Strong Buy
Price Target N/A

Company Profile

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testos...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 592 7399
Address:
23150 Fashion Drive, Suite 232, Estero, United States
juned
juned Dec. 5 at 12:17 PM
0 · Reply
juned
juned Dec. 5 at 12:16 PM
0 · Reply
METS1
METS1 Dec. 5 at 11:55 AM
$ASBP If you don't buy ASBP right now at this price I believe you will regret it down the road. Just look what is happening with all the good news that is coming out.
1 · Reply
W2Cap
W2Cap Dec. 5 at 11:03 AM
$ASBP Not much in terms of updates, apart from the following: 1. Appointment of Dr Mark Jaroszewski, a pioneer in in-vivo drug delivery - don't take my word for it go on ChatGPT or Grok/gemini and search up his history and credentials. 2. FDA 505(b)(2) allows drug delivery methods to bypass the usual ph1/2/3, because it's not a new drug - no need for the FDA to verify the safety profile of Aspirin or a GLP1, for obvious reasons. 3. They have submitted all of the information needed for this; response 2nd January. 4. They just put the wheels in motion for a stock resale (not an offering - very different), allowing management to sell existing shares in bulk to a third party. 5. CPHI meetings with large pharmaceutical companies. 6. ELOC in place to bolster cash position. 7. Quarterly update confirming every single one of these points noted. - All of the above is not conjecture, it is fact, confirmed officially by the business themselves. Go read it yourself don't just trust me.
0 · Reply
Parishay0930
Parishay0930 Dec. 5 at 10:53 AM
$ASBP any materialistic hope or all talks, no movement
0 · Reply
chinesechickenballz
chinesechickenballz Dec. 5 at 10:47 AM
0 · Reply
W2Cap
W2Cap Dec. 5 at 9:36 AM
$ASBP the question was whether licensing before FDA approval is positive. 100% 1. It shows that the licensee is positive about the outcome. 2. It will probably involve an equity for said party - pharma buys a stake in Aspire. 3. This means future dilution unlikely. 4. Big pharma has the Business Development, clout, and brand to be able to put this patented technology in front of the right people in the right places, quickly. Nobody is listening to Aspire pharma but if Bayer etc put their name to it - different story. 5. Share price appreciation, maybe even a future buy out. Of course giving a big pharma a major equity stake would involve having to raise that somehow... There'd be signs. Like a stock resale or something. 🤔🤔
0 · Reply
Turkeymilitary
Turkeymilitary Dec. 5 at 7:42 AM
1 · Reply
Desertlaw
Desertlaw Dec. 5 at 6:13 AM
0 · Reply
Desertlaw
Desertlaw Dec. 5 at 6:09 AM
$ASBP 100 watchers increased within 1-2 days
0 · Reply
Latest News on ASBP
Aspire Biopharma Provides Q3 2025 Business Update

Dec 4, 2025, 9:00 AM EST - 22 hours ago

Aspire Biopharma Provides Q3 2025 Business Update


Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Oct 2, 2025, 2:44 PM EDT - 2 months ago

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher


Aspire Biopharma Holdings, Inc. Announces CEO Transition

Jul 30, 2025, 7:45 PM EDT - 4 months ago

Aspire Biopharma Holdings, Inc. Announces CEO Transition


juned
juned Dec. 5 at 12:17 PM
0 · Reply
juned
juned Dec. 5 at 12:16 PM
0 · Reply
METS1
METS1 Dec. 5 at 11:55 AM
$ASBP If you don't buy ASBP right now at this price I believe you will regret it down the road. Just look what is happening with all the good news that is coming out.
1 · Reply
W2Cap
W2Cap Dec. 5 at 11:03 AM
$ASBP Not much in terms of updates, apart from the following: 1. Appointment of Dr Mark Jaroszewski, a pioneer in in-vivo drug delivery - don't take my word for it go on ChatGPT or Grok/gemini and search up his history and credentials. 2. FDA 505(b)(2) allows drug delivery methods to bypass the usual ph1/2/3, because it's not a new drug - no need for the FDA to verify the safety profile of Aspirin or a GLP1, for obvious reasons. 3. They have submitted all of the information needed for this; response 2nd January. 4. They just put the wheels in motion for a stock resale (not an offering - very different), allowing management to sell existing shares in bulk to a third party. 5. CPHI meetings with large pharmaceutical companies. 6. ELOC in place to bolster cash position. 7. Quarterly update confirming every single one of these points noted. - All of the above is not conjecture, it is fact, confirmed officially by the business themselves. Go read it yourself don't just trust me.
0 · Reply
Parishay0930
Parishay0930 Dec. 5 at 10:53 AM
$ASBP any materialistic hope or all talks, no movement
0 · Reply
chinesechickenballz
chinesechickenballz Dec. 5 at 10:47 AM
0 · Reply
W2Cap
W2Cap Dec. 5 at 9:36 AM
$ASBP the question was whether licensing before FDA approval is positive. 100% 1. It shows that the licensee is positive about the outcome. 2. It will probably involve an equity for said party - pharma buys a stake in Aspire. 3. This means future dilution unlikely. 4. Big pharma has the Business Development, clout, and brand to be able to put this patented technology in front of the right people in the right places, quickly. Nobody is listening to Aspire pharma but if Bayer etc put their name to it - different story. 5. Share price appreciation, maybe even a future buy out. Of course giving a big pharma a major equity stake would involve having to raise that somehow... There'd be signs. Like a stock resale or something. 🤔🤔
0 · Reply
Turkeymilitary
Turkeymilitary Dec. 5 at 7:42 AM
1 · Reply
Desertlaw
Desertlaw Dec. 5 at 6:13 AM
0 · Reply
Desertlaw
Desertlaw Dec. 5 at 6:09 AM
$ASBP 100 watchers increased within 1-2 days
0 · Reply
Desertlaw
Desertlaw Dec. 5 at 5:26 AM
0 · Reply
MRC19
MRC19 Dec. 5 at 5:16 AM
$ASBP BEWARE of this charlatan!! This evil liar is so full of BS… Caught out in countless LIES already and isn’t even a INVESTOR
0 · Reply
MRC19
MRC19 Dec. 5 at 5:11 AM
$ASBP post up that position then big guy…
1 · Reply
OJ_ATX
OJ_ATX Dec. 5 at 5:09 AM
$ASBP news in the am...
0 · Reply
juned
juned Dec. 5 at 3:30 AM
$ASBP the licensing can happen before fda approval if a company wants to get in cheap, also internationally.
1 · Reply
Santa_Claus_Trades
Santa_Claus_Trades Dec. 5 at 3:26 AM
$ASBP In at .0901 with a nice starter. GLTA!
1 · Reply
Bearfaith
Bearfaith Dec. 5 at 3:14 AM
$ASBP Submitted its Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration (FDA). The submission concerns the Company's lead product candidate, a fast-acting, high-dose sublingual aspirin formulation for the treatment of suspected acute myocardial infarction (AMI) and represents a significant milestone on the path to potential FDA approval. On November 13, 2025, the FDA responded positively to the request and stated it would provide written responses in lieu of a meeting no later than January 2, 2026.
0 · Reply
Dannyfor
Dannyfor Dec. 5 at 3:14 AM
$ASBP - up to 8,000 shares. I’ll keep loading up. Any technology that delivers life saving medication faster is worth a shot!
1 · Reply
Invest2Create
Invest2Create Dec. 5 at 2:34 AM
While we’re waiting on $ASBP, does this below sound familiar? $IXHL has simply a smaller version of $ASBP’s catalysts and potential. The difference is $IXHL’s catalysts are happening now, rather than possibly months from now. So, one can either wait with $ASBP shares earning essentially nothing for weeks to months while its catalysts develop; or, come on over to $IXHL for even a week or two, likely double your money or more, then buy up double the shares of $ASBP as it gets closer to making news and moving markets, while finding Aspire’s shares virtually just where you left them. What’s not to like? Welcome to the world of swing trading.
0 · Reply
beachbroke
beachbroke Dec. 5 at 12:55 AM
$ASBP need to get above 10 cents or we will be looking at a delisting notice before to long.
0 · Reply
MsReina
MsReina Dec. 5 at 12:19 AM
My current line up is $ASBP $PMCB $SNSE $DEVS 🔥
0 · Reply
MsReina
MsReina Dec. 4 at 11:12 PM
0 · Reply